Your session is about to expire
Qvar vs Symbicort
Introduction
For patients with chronic respiratory conditions such as asthma or COPD (Chronic Obstructive Pulmonary Disorder), certain medications that control and reduce inflammation in the lungs can help manage symptoms and prevent exacerbations. Qvar and Symbicort are two such drugs that are commonly prescribed for these conditions. Both work by reducing inflammation in the airways, but they affect different aspects of lung function.
Qvar is a corticosteroid inhaler also known as beclomethasone dipropionate. It works primarily by minimizing inflammation in the bronchial tubes, making it easier for patients to breathe and preventing asthma attacks from occurring.
Symbicort, on the other hand, is a combination medication containing budesonide (a corticosteroid) and formoterol (a long-acting beta agonist). This dual-action drug not only reduces lung inflammation like Qvar does but also relaxes muscles around the airways to open them up more effectively. The additional benefit of having a long-acting bronchodilator makes Symbicort suitable for controlling severe or persistent symptoms.
Qvar vs Symbicort Side By Side
| Attribute | Qvar | Symbicort |
|---|---|---|
| Brand Name | Qvar | Symbicort |
| Contraindications | Should not be taken if using or have recently used oral corticosteroids, patients with heart diseases, and people with diabetes | Should not be taken if using or have recently used oral corticosteroids, patients with heart diseases, and people with diabetes |
| Cost | $200 for one inhaler | $300 for one inhaler |
| Generic Name | Beclomethasone dipropionate | Budesonide/formoterol |
| Most Serious Side Effect | Severe allergic reactions, vision problems, cardiovascular symptoms, breathing problems, signs of infection, adrenal insufficiency | Signs of an allergic reaction, chest pain, fast or irregular heartbeats, tremors and nervousness, choking or other breathing problems, white patches in the mouth or throat, blurred vision |
| Severe Drug Interactions | Not specifically mentioned, but caution advised with recent oral corticosteroid use | Not specifically mentioned, but caution advised with recent oral corticosteroid use |
| Typical Dose | 40–320 mcg/day | Two inhalations of 80/4.5 mcg or 160/4.5 mcg, twice daily |
What is Qvar?
Beclomethasone dipropionate (the generic name for Qvar) is a type of inhaled corticosteroid used to control and prevent symptoms such as shortness of breath and wheezing caused by asthma. It was first approved by the FDA in 2000. Qvar works by reducing swelling, inflammation, and irritation in the airways, making breathing easier over time. It is prescribed for long-term management of asthma symptoms.
On the other hand, Symbicort is a combination medication containing both an inhaled corticosteroid (budesonide) along with a bronchodilator (formoterol). This dual action not only reduces inflammation but also relaxes muscles around the airways to improve breathing immediately. Therefore, Symbicort offers quick relief from acute symptoms while maintaining long-term control over chronic ones.
While both medications are effective treatments for controlling asthma symptoms, they work differently due to their individual components' actions. The presence of formoterol in Symbicort provides rapid symptom relief that isn't found with Qvar alone; however this may result in additional side effects such as tremors or palpitations.
What conditions is Qvar approved to treat?
Qvar and Symbicort are both approved for the treatment of various respiratory conditions, such as:
- Asthma, a long-term disease of the airways in the lungs
- Chronic Obstructive Pulmonary Disorder (COPD), which includes chronic bronchitis and emphysema. Note that Qvar is not typically first-line therapy for COPD while Symbicort is commonly used.
- Both drugs can be used as maintenance treatments to help prevent asthma attacks or worsening symptoms in COPD, but they have differences in their active ingredients and dosing frequencies.
It's important to note that neither Qvar nor Symbicort should be used as a rescue inhaler to relieve sudden breathing problems.
How does Qvar help with these illnesses?
Qvar aids in managing asthma by delivering a corticosteroid named beclomethasone directly to the lungs. The medication works by reducing inflammation, thereby minimizing swelling and irritation within the airways and helping them remain open and clear for easier breathing. Inflammation in the lungs can lead to asthma symptoms such as wheezing, coughing, shortness of breath, and chest tightness. On the other hand, Symbicort contains two active ingredients: budesonide (a corticosteroid) that reduces inflammation similar to Qvar's function but also includes formoterol which is a long-acting bronchodilator that helps relax muscles around your airways for up to 12 hours. This dual-action makes Symbicort effective at both preventing asthma symptoms while providing immediate relief from existing ones.
What is Symbicort?
Symbicort is a brand name for a combination of budesonide and formoterol. Budesonide is a corticosteroid that decreases inflammation, while formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs) which help to relax muscles in the airways, thus improving breathing. Symbicort was first approved by the FDA in 2006 and it's primarily used to prevent bronchospasm in patients with asthma or chronic obstructive pulmonary disease (COPD).
Unlike Qvar which contains only beclomethasone, a type of corticosteroid, Symbicort has the additional benefit of formoterol - making it more effective at both reducing inflammation and relaxing airway muscles. This dual-action results in improved lung function and fewer symptoms such as wheezing and shortness of breath.
However, these benefits come with potential side effects including throat irritation or pain, change in voice, muscle cramps or tremors. It's important to note that everyone’s response will vary; some people may experience these side-effects while others may not.
What conditions is Symbicort approved to treat?
Symbicort is a medication that has received approval for the treatment of:
- Chronic obstructive pulmonary disease (COPD), inclusive of chronic bronchitis and emphysema
- Asthma in patients who are at least 6 years old, especially when less aggressive treatments have not been effective enough. This drug should be used with caution as it is not designed to relieve sudden breathing problems.
How does Symbicort help with these illnesses?
Symbicort, a combination of budesonide and formoterol, is used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) and asthma. Budesonide belongs to the class of drugs known as corticosteroids, which reduce inflammation in the airways making breathing easier. Formoterol belongs to a group of medicines called long-acting bronchodilators that relaxes muscles in the airways to improve airflow. Together they manage symptoms like wheezing, shortness of breath, and difficulty breathing more effectively than single-component inhalers such as Qvar.
The dual action of Symbicort makes it stand out from other medications; while Qvar only contains beclomethasone - a steroid that reduces inflammation - Symbicort's additional long-acting bronchodilator component helps with immediate symptom relief by widening the air passages in your lungs. This means it can be an effective choice when patients do not respond well enough to single-component steroids alone or need additional help managing their symptoms.
How effective are both Qvar and Symbicort?
Both Qvar (beclomethasone dipropionate) and Symbicort (budesonide/formoterol) are commonly prescribed medications for the treatment of asthma, with both having been approved by the FDA within a decade of each other. They utilize different mechanisms to manage asthma symptoms; Qvar is an inhaled corticosteroid that reduces inflammation, while Symbicort combines a corticosteroid (budesonide) with a long-acting beta2-adrenergic agonist (formoterol) to both reduce inflammation and relax airway muscles.
A 2017 clinical trial comparing beclomethasone dipropionate with budesonide/formoterol found similar efficacy between these two drugs in controlling mild persistent asthma symptoms. Safety profiles also appeared comparable, but it's important to note that due to its dual-action mechanism, Symbicort may carry additional risks related to formoterol use such as increased heart rate or palpitations.
In terms of their individual merits: A meta-analysis from 2009 demonstrated that beclomethasone is effective at reducing acute exacerbations and improving overall lung function when used regularly. It’s considered well-tolerated and safe for long-term use even among pediatric populations.
On the other hand, according to a comprehensive review conducted in 2016, budesonide/formoterol has shown consistent benefits over placebo in managing moderate-to-severe persistent asthma as well as chronic obstructive pulmonary disease (COPD). While often reserved for more severe cases or those not adequately controlled on single-agent therapy due its inclusion of formoterol - which can potentially increase certain side effects - it provides additional bronchodilation effects that could benefit patients who struggle primarily with constricted airways.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Qvar typically prescribed?
Inhaled dosages of Qvar range from 40–320 mcg/day, with studies indicating that 80 mcg/day is generally sufficient for managing asthma in most people. Children over the age of 5 may be started on a lower dosage of 40 mcg/day. In both adults and children, the dosage can be increased after a few weeks if there is no response. The maximum daily dose should not exceed 640 mcg.
Symbicort inhalation doses typically range from two puffs of Symbicort twice daily (up to four times in severe cases). For children aged six years or older and adolescents, it's usually one puff twice per day. Dosage adjustments are based on individual response but should neither exceed nor fall below prescribed amounts without medical consultation.
At what dose is Symbicort typically prescribed?
Symbicort treatment typically begins with two inhalations of the 80/4.5 mcg dosage, twice daily, morning and evening. Dose can then be increased to two inhalations of the 160/4.5 mcg dose if necessary, again taken in the morning and evening. The maximum recommended dose is four inhalations of either strength per day (either 320/18 mcg or 640/18 mcg), which may be considered if there's no significant improvement after a few weeks at lower doses. As always, any changes to medication should only be made under medical supervision.
What are the most common side effects for Qvar?
Some common side effects of Qvar can include:
- Throat irritation or pain
- Changes in voice, particularly hoarseness
- Cough
- Headache
- Upset stomach
On the other hand, Symbicort may cause:
- Upper respiratory tract infection or inflammation
- Nasopharyngitis (inflammation of the nose and pharynx)
- Headache
- Oral thrush (a fungal infection in the mouth)
- Bronchitis
- Sinusitis (inflammation of the sinus cavities in the head)
It is crucial to note that not everyone experiences these side effects, and some people might experience different ones. If you have any concerns about a medication's side effects, it is essential to discuss them with your healthcare provider before starting treatment.
Are there any potential serious side effects for Qvar?
While both Qvar and Symbicort are used to treat asthma, they may have different side effects. For example, in rare cases, Qvar and Symbicort can cause serious health issues such as:
- Severe allergic reactions: symptoms include hives, difficulty breathing or swallowing, swelling of the face or throat
- Vision problems: blurred vision could be a sign of a serious eye problem
- Cardiovascular symptoms: rapid heart rate or palpitations
- Breathing problems: increased wheezing after using this medicine; symptoms might indicate that your condition is getting worse
- Signs of infection - fever, chills, cough with yellow/green mucus production
In extremely rare instances these medications can cause adrenal insufficiency. Symptoms for which include severe fatigue/weakness, nausea/vomiting/diarrhea.
If you experience any of these symptoms while taking either medication it's important to seek immediate medical attention.
What are the most common side effects for Symbicort?
Symbicort, compared to Qvar, may have a different set of side effects including:
- Throat irritation or dryness
- Changes in voice such as hoarseness
- Stomach discomfort and nausea
- Headache or dizziness
- Tremors or nervousness
- Difficulty sleeping (insomnia)
- Fast heartbeat. Remember that not everyone experiences these side effects and they can often be managed with appropriate care. However, if symptoms persist or worsen, it's essential to get medical help immediately.
Are there any potential serious side effects for Symbicort?
While Symbicort is generally well tolerated, it can occasionally cause serious side effects. These may include:
- Signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat
- Chest pain, fast or irregular heartbeats
- Tremors and nervousness
- Choking or other breathing problems after using this medicine
- White patches in the mouth or throat (indicative of a fungal infection)
- Blurred vision, tunnel vision, eye pain or redness; seeing halos around lights (signs of glaucoma)
If you experience any severe symptoms while using Symbicort please seek medical attention immediately.
Contraindications for Qvar and Symbicort?
Both Qvar and Symbicort, like most other asthma medications, may worsen symptoms of asthma in certain individuals. If you notice your asthma symptoms worsening or an increase in the frequency of attacks, please seek immediate medical attention.
Neither Qvar nor Symbicort should be taken if you are using, or have recently used oral corticosteroids. Always inform your physician about any medications you are currently taking; there needs to be a proper gap between discontinuation of oral steroids and initiation of inhaler-based corticosteroids to prevent adrenal insufficiency.
Furthermore, patients with heart diseases need to exercise caution while using these medications as they can cause palpitations or rapid heartbeat. Both drugs require careful use among people with diabetes due to potential impact on blood sugar levels. Always discuss your complete health history with your healthcare provider before starting treatment with either medication.
How much do Qvar and Symbicort cost?
For the brand name versions of these drugs:
- The cost of Qvar Redihaler (beclomethasone dipropionate) averages around $200 for one inhaler, which typically lasts a month. This works out to approximately $6-$7/day depending on your dose.
- The price for Symbicort (budesonide/formoterol) is about $300 for one inhaler, which also usually lasts a month, working out to roughly$10/day.
If you are in the higher dosage range for Qvar (i.e., 320 mcg/day or higher), then brand-name Symbicort might be less expensive on a per-day treatment basis. However, it's crucial to remember that cost should not be the primary consideration when determining which medication is best suited for you.
Regarding generic versions of these medications:
- Currently no generic equivalent exists for either Qvar or Symbicort in the United States market due to patent protection and other factors affecting drug availability.
Please note that prices can vary widely depending upon insurance coverage and pharmacy location. Consult with your healthcare provider and pharmacist regarding all potential costs associated with each medication option before making any decisions.
Popularity of Qvar and Symbicort
Beclomethasone dipropionate, also known by its brand name Qvar, was estimated to have been prescribed to about 3.4 million people in the US in 2020. Beclomethasone accounted for nearly 15% of all inhaled corticosteroids prescriptions in the US and remains a popular choice due to its effectiveness as an asthma controller medication.
On the other hand, Budesonide/Formoterol Fumarate Dihydrate is commonly known by its brand name Symbicort. It was prescribed to approximately 5 million people in the USA throughout 2020, accounting for around 22% of combination inhaler prescriptions (an inhaler that combines a long-acting bronchodilator and a steroid). The prevalence of Symbicort has seen steady growth over recent years owing largely to its dual-action mechanism which provides both immediate relief from symptoms while controlling inflammation over time.
Conclusion
Both Qvar (beclomethasone) and Symbicort (budesonide/formoterol) are commonly used in the long-term management of asthma, with a wealth of clinical studies supporting their efficacy compared to placebo treatments. In some instances, these medications may be combined for more effective control of severe symptoms but this would require careful consideration by a healthcare provider due to potential drug-drug interactions. Due to their different mechanisms of action—with Qvar being an inhaled corticosteroid that reduces inflammation in the lungs, and Symbicort containing both a corticosteroid (budesonide) and a long-acting beta agonist (formoterol)—they are prescribed under varying circumstances.
Qvar is often considered as first-line maintenance therapy for persistent asthma while Symbicort is typically prescribed when control cannot be achieved with low-to-medium doses of inhaled corticosteroids alone or for patients who have frequent exacerbations despite adhering to their medication regimen.
Both drugs are available as generics which can lead to significant cost-savings especially for those paying out-of-pocket. Both Qvar and Symbicort may necessitate an adjustment period where maximum benefits might not be immediately evident.
The side effect profiles between the two medications bear similarities—being generally well-tolerated—but it's worth noting that because Symbicort contains formoterol, there can be additional side effects such as shaking or tremors, nervousness, and fast heartbeat. As always, patients need to monitor themselves closely after starting treatment or adjusting dosages and should seek immediate medical help if they notice worsening symptoms or develop unexpected side effects.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Nobata, K., Fujimura, M., Myou, S., Ishiura, Y., Mizuguchi, M., Nishi, K., & Nakao, S. (2006, January). Bronchial Asthma Showing Reduction in FEV<sub>1</sub>after Inhalation of Qvar™. Journal of Asthma. Informa UK Limited.http://doi.org/10.1080/02770900600710722
- Buhl, R. (2003, August). Budesonide/formoterol for the treatment of asthma. Expert Opinion on Pharmacotherapy. Informa UK Limited.http://doi.org/10.1517/14656566.4.8.1393
- Chew, K. S., Kamarudin, H., & Hashim, C. W. (2012, April 13). A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks. International Journal of Emergency Medicine. Springer Science and Business Media LLC.http://doi.org/10.1186/1865-1380-5-16
- Berger, W. E., & Noonan, M. J. (2010, May). Treatment of Persistent Asthma With Symbicort® (Budesonide/Formoterol Inhalation Aerosol): An Inhaled Corticosteroid and Long-Acting β<sub>2</sub>-Adrenergic Agonist in One Pressurized Metered-Dose Inhaler. Journal of Asthma. Informa UK Limited.http://doi.org/10.3109/02770901003725684
- Halpin, D. M. (2008, January). Symbicort: a pharmacoeconomic review. Journal of Medical Economics. Informa UK Limited.http://doi.org/10.3111/13696990802210984
- Korn, S., Vogelmeier, C., & Buhl, R. (2008, May). Feste Kombination aus Budesonid und Formoterol in der Erhaltungs- und Bedarfstherapie. Medizinische Klinik. Springer Science and Business Media LLC.http://doi.org/10.1007/s00063-008-1050-y
- Bateman, E. D., Bantje, T. A., Gomes, M. J., Toumbis, M. G., Huber, R. M., Naya, I., & Eliraz, A. (2003, June). Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma. American Journal of Respiratory Medicine. Springer Science and Business Media LLC.http://doi.org/10.1007/bf03256655
- Emami, M., Tayebi, A., Gharipour, M., Farzamnia, S., & Temyarti, A. (2014). Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control. Advanced Biomedical Research. Medknow.http://doi.org/10.4103/2277-9175.127999